Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.
JAMA Psychiatry March 1, 2025 Michelle Matvey, Dennis Parker Kelley, Ellen Bradley et al. 12 citations
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment...